Drugs that contain Enzalutamide
1. Drug name - XTANDI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7709517 | ASTELLAS | Diarylhydantoin compounds |
Aug, 2027
(4 years from now) | |
| CN102584712A | ASTELLAS | Diaryl Hydantoin Compound |
Nov, 2015
(6 years ago) | |
| CN105037273B | ASTELLAS | Diaryl Hydantoin Compound |
Mar, 2026
(3 years from now) | |
| CN101222922A | ASTELLAS | Diarylhydantoin Compounds |
Mar, 2026
(3 years from now) | |
| CN101222922B | ASTELLAS | Diaryl Hydantoin Compounds |
Mar, 2026
(3 years from now) | |
| CN105037273A | ASTELLAS | Diaryl Hydantoin Compound |
Mar, 2026
(3 years from now) | |
| CN102755318A | ASTELLAS | Diaryl Thiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| CN102755318B | ASTELLAS | Diarylthiohydantoin Compound |
Mar, 2027
(4 years from now) | |
| CN101460467A | ASTELLAS | Diarylthiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| CN101460467B | ASTELLAS | Diarylthiohydantoin Compound |
Mar, 2027
(4 years from now) | |
| EP2444085A1 | ASTELLAS | Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer |
Jun, 2016
(6 years ago) | |
| EP2444085B1 | ASTELLAS | Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer |
Jun, 2016
(6 years ago) | |
| EP1893196B2 | ASTELLAS | Diarylhydantoin Compound |
Mar, 2026
(3 years from now) | |
| EP1893196A1 | ASTELLAS | Diarylhydantoin Compound |
Mar, 2026
(3 years from now) | |
| EP1893196B1 | ASTELLAS | Diarylhydantoin Compound |
Mar, 2026
(3 years from now) | |
| EP1893196A4 | ASTELLAS | Diarylhydantoin Compounds |
Mar, 2026
(3 years from now) | |
| EP2656842A3 | ASTELLAS | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2013187A2 | ASTELLAS | Diarylthiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| EP2013187B1 | ASTELLAS | Diarylthiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126941 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
May, 2026
(3 years from now) | |
| US8183274 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
Aug, 2026
(3 years from now) | |
Treatment: Treatment of patients with castration-resistant prostate cancer (crpc); the treatment of patients with metastatic castration-resistant prostate cancer (crpc).; the treatment of patients with metastatic castration-sensitive prostate cancer; The treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel; the treatment of patients with metastatic castration-resistant prostate cancer (crpc).; the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc)
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 40MG | TABLET;ORAL | Prescription |
| 80MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.